Lucy Barker

TL;DR: Dysregulation of a broad range of inflammatory mediators in idiopathic and familial PAH demonstrates that cytokine levels have a previously unrecognized impact on patient survival and cytokines may prove to be useful biomarkers and provide insight into the contribution of inflammation in PAH.

TL;DR: It is established that BMPR-II deficiency leads to failed growth suppression by TGF-β1 in PASMCs, and a rationale to test anti-interleukin therapies as an intervention to neutralize this inappropriate response and restore the antiproliferative response to TGF -β1 is provided.

TL;DR: High throughput screening identified a 7-azaindole-3-acetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a highly selective compound with good functional potency for inhibition of human eosinophil shape change in whole blood and oral bioavailability in the rat.

TL;DR: A series of novel corticosteroid derivatives featuring C-17 furoate ester functionality have been synthesised and profiling in vitro and in vivo has resulted in the identification of a compound with a longer duration of action and a lower oral side effect profile in rodents compared to budesonide.

TL;DR: A follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid is discovered, which exhibits improved potency on human eosinophils and Th2 cells, together with a longer receptor residence time, and is currently in clinical trials for severe asthma.